An observational study in Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection and Pneumonia, sponsored by Sichuan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Sichuan Provincial People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.
Among the 286 studies in Sepsis with a site in China, this one is the 73rd largest by planned enrollment of the 164 observational ones that give a count, is one of 20 that started in 2025, is one of 165 observational ones, reaches primary completion later than 74 of the 105 other live ones, and was the 256th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 15 · Phase 4 17
First in 2004; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 118 across the 121 interventional studies, 180 across the 164 observational. Of the 87 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 286 have an industry lead sponsor. The 10 most frequent:
Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.
Sichuan Provincial People's Hospital has 5 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
26 of the studies in Sepsis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089186Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | 2026-12 |
| NCT05623722Jing Cai, MDErector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury | 2026-11-30 |
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 286 studies in Sepsis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.
The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.
To reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.
This is a single-center real-world observational cohort study including hospitalized adult patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients will be classified into two groups based on treatment exposure: those receiving sulbactam-durlobactam and those receiving alternative anti-CRAB regimens during the same period.
The study aims to evaluate the effectiveness and safety of sulbactam-durlobactam in high-risk populations, including transplant recipients and critically ill patients. The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, ICU length of stay, duration of mechanical ventilation, and treatment-related adverse events.
To minimize bias inherent in observational studies, propensity score matching, inverse probability of treatment weighting (IPTW), and multivariable regression models will be applied to adjust for baseline differences between groups. Landmark analysis will be conducted to address time-related biases.
A nested therapeutic drug monitoring (TDM) sub-cohort will be included. Plasma samples will be collected at predefined time points within a dosing interval, and drug concentrations will be measured using validated LC-MS/MS methods. Population pharmacokinetic modeling will be performed to estimate exposure parameters, including Cmin, Cmax, and AUC. The relationship between drug exposure and clinical outcomes, as well as PK/PD target attainment, will be further explored.
Subgroup analyses will be conducted according to infection status (confirmed infection vs. donor-derived colonization or infection).
Hospitalized adult patients receiving anti-CRAB antimicrobial therapy in real-world clinical practice, including:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:
Exclusion Criteria:
Patients receiving sulbactam-durlobactam within 48 hours after treatment initiation.
Drug: Sulbactam-Durlobactam
Patients receiving alternative anti-CRAB regimens during the same period without sulbactam-durlobactam.
Sulbactam-durlobactam administered according to routine clinical practice for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infection.
28-day All-Cause Mortality
All-cause mortality occurring within 28 days after initiation of anti-CRAB therapy.
Time frame: Up to 28 days after initiation of anti-CRAB therapy
Clinical Failure
Clinical failure defined as lack of clinical improvement, need for escalation of antimicrobial therapy, or death.
Time frame: Up to 28 days after initiation of anti-CRAB therapy
Length of ICU stay
Duration of ICU stay measured from ICU admission to ICU discharge.
Time frame: Up to 90 days after ICU admission
Time to clinical improvement
Time from initiation of anti-CRAB therapy to predefined clinical improvement.
Time frame: Up to 28 days after initiation of anti-CRAB therapy
Microbiological eradication
Microbiological eradication confirmed by follow-up culture negativity.
Time frame: Up to 14 days after initiation of anti-CRAB therapy
Plan to share: No — Individual participant data will not be shared due to institutional policies and patient privacy protection.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Provincial People's Hospital